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New BMJ policy on economic evaluations
Response of NHS Economic Evaluation
Database Research Team
Editor—We, the NHS Economic Evaluation
Database Research Team, agree with Smith
that economic evaluations should contain
comprehensive reporting of both clinical
effectiveness and economic analysis and that
the BMJ is right to implement this new
policy.1 How the clinical trial results (which
inform the economic evaluation) are
obtained is often paramount to the under-
standing and quality of the economic analy-
sis conducted.2
Research reports are included and
abstracted in full on the NHS Economic
Evaluation Database (www.york.ac.uk/inst/
crd)—if they explicitly report costs and clini-
cal outcomes for an intervention and at least
one comparator.3 However, to critique the
method adopted in the effectiveness study
underpinning the economic evaluation
appropriately, our template requires infor-
mation that is often omitted in the report of
the economic evaluation. When the parent
clinical study has been previously published
elsewhere, we obtain the study and use that
alongside the economic research when writ-
ing the abstract. The abstract on the
database then provides information on sam-
ple selection, study design, method of analy-
sis, and so on, with the fact that the relevant
information is cited from the parent study.
Adhering to published guidelines, such
as those provided by the BMJ,4 should
produce publications of the highest quality,
but authors are still likely to feel the need to
be selective in their reporting, given word
limits. If authors are required to report more
effectiveness data other crucial aspects of the
economic evaluation might receive less
attention. The focus for BMJ editors should
be to ensure that reporting of both
important components of economic evalua-
tions receives appropriate attention from
the authors.
If the policy results in full reporting of
both clinical and economic results in one
place—for example, two papers in one issue
of the journal—this will constitute an
improvement. If, however, the new policy
results in the combination of clinical and
economic results in one short paper, this
may be a step backwards.
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Will the BMJ return clinical trials if
submitted without any economic results?
Editor—The implications of the BMJ’s new
policy for economic evaluations are
unclear.1
Firstly, a lag often exists between the
clinical and economic results, making simul-
taneous submission difficult. Typically, clini-
cians are eager to disseminate important
clinical results immediately. For example, the
extracorporeal membrane oxygenation
(ECMO) trial was among the first research
projects to incorporate economic evaluation
in its design from the outset. But the
preliminary clinical results were written up
and fast tracked to the Lancet before I was
even employed to continue the economic
evaluation.2 The economic evaluation was
published in the BMJ years later, having
required the clinical evidence in its analysis
and appropriate sensitivity analyses and
having undergone delay to publication.3
Would it have benefited anyone to with-
hold dramatic clinical results until the
economic results were ready? Clinical results
are often more generalisable to an inter-
national audience than the concurrent
economic results. The limitations of any
clinical information in the absence of
economic evidence should be made explicit.
The pertinent concern is surely to ensure
relevant policy makers exercise restraint
until the full information is available.
Secondly, no incentive is given in the
BMJ policy for clinicians to change their
practice. Presumably clinicians send results
to the Lancet for higher impact factors and
wider dissemination. If economists cannot
persuade colleagues to submit the clinical
paper alongside the economic paper to the
BMJ, they will resort to submitting results to
economic journals for which a different style
for different specialist audiences would be
required, ensuring even poorer dissemina-
tion to clinical audiences and policy makers.
Finally, your editorial emphasised strong
support for keeping clinical and economic
results together, and Smith told us to send
“somebody else your clinical results and us
your economic results, and we will send
them back, politely.” May I therefore ask,
politely, is the converse also true? Will you
return clinical trials if submitted without any
economic results?
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Economic evaluations should be judged
on scientific merit
Editor—Health economists have been
grateful for the BMJ’s hitherto supportive
stance towards the publication of economic
evaluations. The proposed new policy not to
publish economic evaluations unless also
offered the clinical results is disappointing
and misjudged.1
Firstly, this policy denies the fact that,
although clinical and economic results from
a trial are both components of an overall
evaluation, they also have many differences,
often including the funding agencies sup-
porting them, the researchers, and the
timescale over which they are performed
and published. Perhaps most importantly,
important trials are often prepared for an
international audience, but economic evalu-
ations usually relate to specific healthcare
systems; large trials may generate the need
for several country specific economic evalu-
ations.
These differences justify researchers in
choosing to submit clinical and economic
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